Iceland's DeCode Genetics says that an early-stage trial of DG051 for preventing heart attacks demonstrated that it was well tolerated at all levels with no significant adverse events. The experimental therapy is a follow-up drug to DG031, a late-stage therapy that encountered formulation trouble in Phase III. Report